Research Article
Selective Interactions of Valeriana officinalis Extracts and Valerenic Acid with $[^3\text{H}]$Glutamate Binding to Rat Synaptic Membranes

Lisa M. Del Valle-Mojica,1 Yoshira M. Ayala-Marín,2 Carmen M. Ortiz-Sanchez,3 Bianca A. Torres-Hernández,1 Safa Abdalla-Mukhaimer,1 and José G. Ortiz1

1 Department of Pharmacology and Toxicology, School of Medicine, University of Puerto Rico-Medical Sciences Campus, P.O. Box 365067, San Juan 00936-5067, Puerto Rico
2 Department of Biology, Natural Sciences Faculty, University of Puerto Rico Humacao Campus, Humacao 00791-4300, Puerto Rico
3 Department of Chemistry, Natural Sciences Faculty, University of Puerto Rico Cayey Campus, Cayey 00736-9997, Puerto Rico

Received 29 October 2010; Accepted 12 February 2011

Although GABA neurotransmission has been suggested as a mechanism for Valeriana officinalis effects, CNS depression can also be evoked by inhibition of ionotropic (iGluR) and metabotropic glutamate receptors (mGluR). In this study, we examined if aqueous valerian extract interacted with glutamatergic receptors. Freshly prepared aqueous valerian extract was incubated with rat cortical synaptic membranes in presence of 20 nM $[^3\text{H}]$Glutamate. Aqueous valerian extract increased $[^3\text{H}]$Glutamate binding from $1 \times 10^{-7}$ to $1 \times 10^{-3}$ mg/mL. In the presence of (2S,1′S,2′S)-2-(Carboxycyclopropyl)glycine (LCCG-I) and (2S,2′R,3′R)-2-(2′,3′-Dicarboxycyclopropyl)glycine (DCG-IV), Group II mGluR agents, valerian extract markedly decreased $[^3\text{H}]$Glutamate binding, while (2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl) propanoic acid) (quisqualic acid, QA), Group I mGluR agonist, increased $[^3\text{H}]$Glutamate binding. At 0.05 mg/mL aqueous valerian extract specifically interacted with kainic acid NMDA and AMPA receptors. Valerenic acid, a marker compound for Valeriana officinalis, increased the $[^3\text{H}]$Glutamate binding after $1.6 \times 10^{-2}$ mg/mL, and at 0.008 mg/mL it interacted only with QA (Group I mGluR). The selective interactions of valerian extract and valerenic acid with Group I and Group II mGluR may represent an alternative explanation for the anxiolytic properties of this plant.

1. Introduction

Valeriana officinalis L., s.l. (Valerianaceae family) is a medicinal plant used in complementary and alternative medicine for its sedative and anxiolytic properties [1, 2]. Valerian’s effects on the central nervous system have been well documented and attributed to many of its active compounds: valepotriates, baldrinals, valerenic acid, valerenal and valerenone, and other constituents in the essential oils [1, 3–8]. Albeit the anxiolytic properties of valerian have been demonstrated in animals [9, 10], there are no sufficient studies in humans [6]. Consequently, the therapeutic properties of Valeriana officinalis have yet to be conclusively demonstrated [6, 9, 11].
and isoborneol, two constituents present in the extracts. To accomplish this objective, receptor-binding assays were performed using rat cortical synaptic membranes in the presence of fresh valerian extracts and both types of glutamate receptor ligands.

2. Materials and Methods

2.1. Chemicals. Valerencic acid (99.7% purity-Lot no. 22150-1800) and isoborneol (96.6% purity-Lot no. 09195-102) were purchased from Chromadex, Irvine, CA. L-[3,4-3H]-Glutamic acid (49.9 Ci/mmol) was obtained from PerkinElmer Life and Analytical Sciences, Inc. (Shelton, CT). AMPA (RS)-a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), NMDA (N-methyl-D-aspartic acid), kainic acid, quisqualic acid (2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazol-2-yl) propanoic acid), LCCG (2S,1′S,2′S)-2-(Carboxycyclopolyglycine, EGLU ((2S)-a-Ethylglutamic acid), spaglumic acid (N-Acetyl-L-aspartyl-L-glutamic acid) and L-AP4 (L-(+)-2-Amino-4-phosphonobutyric acid) were obtained from Tocris Bioscience (Ellisville, MO). UniverSol ES was obtained from MP Biomedicals (Solon, OH). All other reagents were obtained from Sigma-Aldrich Co. (St. Louis, MO).

2.2. Valerian Extracts. Valeriana officinalis L., s.l. dry powdered roots (Lot. 1111H-OUP), harvested in 2004 and organically grown/certified, were obtained from Pacific Botanicals (LLC Grants Pass, Oregon). Valerian was extracted in ultra pure water, typically (1 : 10 w/v) at −23°C and stirred for 1 hour. Aliquots were centrifuged at 6,700 g to remove particulates.

2.3. Valerenic Acid. A 10 mM stock solution was prepared using EtOH 95%. The dilutions used for the assays were freshly prepared with 50 mMTris-HCl/100 mM KCl buffer before each experiment.

2.4. Isoborneol. A 65 mM stock solution was prepared using EtOH 95%. The dilutions used for the assays were freshly prepared with EtOH 70% before each experiment.

2.5. Cerebral Cortex Synaptic Membranes. Cerebral cortex synaptic membranes were purchased from Analytical Biological Services, Inc. (Wilmington, DE). They report that these were prepared as follows: female rats of approximately two months of age were decapitated and the brain promptly removed. The cortex was dissected and homogenized (1:10 w/v) in ice-cold 10 mM TRIS-HCl buffer pH 7.4. The homogenate was centrifuged twice at 2,500 g for 10 min. The resulting supernatant was centrifuged at 12,500 g for 20 min. The pellet was washed twice with ice-cold 10 mM TRIS-HCl buffer pH 7.4 (1:10 w/v) and centrifuged at 12,500 g for 20 min. The pellet (synaptic membrane, P2) was resuspended in 10 mM TRIS-HCl buffer pH 7.4 and freeze thawed at least three times before being stored at −80°C until used. Protein concentration was determined using the Bradford assay [13] using bovine serum albumin (BSA) as reference standard.

2.6. [3H]Glutamate Binding. Receptor-binding competition assays were done using cerebral cortex synaptic membranes from Analytical Biological Services, Inc. (Wilmington, DE). The reaction was initiated by the addition of tissue (100 μg protein) to tubes containing 1 mM of different iGluR and mGluR ligands and 20 nM [3H]Glutamic acid in a final volume of 500 μL of 50 mM Tris HCl/100 mM KCl buffer, pH 7.4. The nonspecific binding was determined in the presence of 1 mM nonradioactive glutamate. All samples were incubated on ice (0–4°C) for 40 minutes. The assay was stopped by centrifugation for 30 min at 6,700 g; the supernatant was extracted, and the pellet was washed two times with 1 mL of ice-cold buffer. The pellet was resuspended in 500 μL of buffer. Radioactivity of the samples was quantified in a Beckman LS 6500 Multipurpose Scintillation Counter with 1 mL of UniverSol ES scintillation cocktail. Results are shown as percentage of total binding (SEM).

2.7. [3H]Glutamate Displacement Curves. Different concentrations of freshly prepared aqueous valerian extracts (4 pg/mL–12 mg/mL), valerenic acid (30 ng/mL–2 mg/mL), and isoborneol (5 ng/mL–2 mg/mL) were incubated with rat cortical membranes in presence of 20 nM [3H]Glutamate.

2.8. Statistical Analysis. Data were expressed as mean values ± the standard error of the mean (SEM) of at least three experiments. The differences between the experimental
ionsotropic glutamate receptor interactions

![Valerian](image1)

![Valerenic acid](image2)

![Isoborneol](image3)

**Figure 2:** Effects of valerian extracts, valerenic acid, and isoborneol on ionotropic glutamate receptors (iGluR). (a) Valerian extract at 0.05 mg/ml in presence of 1 mM kainic acid (KA) decreased the glutamate binding significantly. This effect was not seen with NMDA or AMPA. High concentrations of valerian extract (10 mg/ml) in presence of NMDA (1 mM) significantly decreased the glutamate binding. Neither AMPA nor KA in presence of higher valerian extract concentrations affected the binding. (b) Valerenic acid at 0.008 mg/mL, in presence of 1 mM NMDA, kainic acid (KA) and AMPA, did not affect the glutamate binding. (c) Isoborneol at 0.0008 mg/mL, in presence of 1 mM NMDA, significantly decreased the glutamate binding. At higher concentration (1 mg/mL), isoborneol marked decreased the glutamate binding in presence of AMPA and KA. *agonist versus agonist* (+ (valerian, valerenic acid, or isoborneol), P<.05; ++P<.01; +++P<.001.

3. Results

3.1. [3H]Glutamate Displacement Curves for Valerian and Its Constituents. The effect of different valerian extract concentrations, valerenic acid and isoborneol in presence of [3H]Glutamate were dose dependent, as shown in Figure 1. Valerian increased [3H]Glutamate binding from $8 \times 10^{-7}$ to $1 \times 10^{-5}$ mg/mL reaching a maximum binding of 160% at 1 $\times 10^{-3}$ mg/mL. At higher valerian concentrations, greater than $1 \times 10^{-5}$ mg/mL, there is a sudden decrease in [3H]Glutamate binding, reaching 50% at 12 mg/mL. In contrast, valerenic acid and isoborneol increased [3H]Glutamate binding at higher concentrations ($1.6 \times 10^{-2}$ to 2 mg/mL).

3.2. In Vitro Receptor Selectivity Studies. Having shown that Valeriana officinalis and its constituents interacted with [3H]Glutamate binding, we examined the type of glutamatergic receptor involved. For this purpose, binding assays were done in presence of different types of ionotropic (iGluR) and metabotropic glutamate receptor (mGluR) ligands. Figure 2(a) shows that Valerian extract at 0.05 mg/ml increased [3H]Glutamate binding by 81%. A decrease (21%) in [3H]Glutamate binding is observed with KA (1 mM) but not with NMDA or AMPA. In the presence of NMDA (1 mM), higher valerian extract concentration (10 mg/mL)
Figure 3: Interactions of valerian extracts, valerenic acid, and isoborneol on metabotropic glutamate receptors (mGluR). (a) At lower concentrations of valerian extract (0.05 mg/mL) in presence of LCCG-I, a Group II metabotropic glutamate receptor agonist, there was a marked decrease in the binding. This effect was not seen with QA and L-AP4. Valerian extracts at 10 mg/mL, in presence of both QA and LCCG-I, significantly decreased the glutamate binding. (b) Valerenic acid concentration at 0.008 mg/mL, in the presence of QA, a Group I metabotropic glutamate receptor agonist, produced a significant increase in the binding. No effects were observed in presence of DCG-IV, LCCG-I, EGLU, and L-AP4. (c) Isoborneol, at 0.0008 and 1 mg/mL increased [3H]Glutamate binding by 49% and 64%, respectively. Isoborneol in the presence of mGluR ligands, indiscriminately interacted with all of them. At 0.0008 mg/mL, isoborneol interacted with QA and markedly decreased (14%) [3H]Glutamate binding. In addition, isoborneol interacted with all the mGluR agonists (LCCG-I, DCG-IV, and spaglumic) and antagonist (EGLU). Isoborneol also strongly interacted with L-AP4 at both concentrations (0.0008 mg/mL and 1 mg/mL) and resulted in an increased [3H]Glutamate binding (37% and 46%, resp.). * agonist versus agonist + (valerian, valerenic acid, or isoborneol), P < .05; ++ P < .01; +++ P < .001.

 Increased the [3H]Glutamate binding significantly (20%). Valerian (10 mg/mL) did not interact with AMPA or KA.

The same assay was performed with 0.008 mg/mL of valerenic acid, and it showed (Figure 2(b)) that valerenic acid decreased the [3H]Glutamate binding more than 40%. However, valeric acid did not change the effects of iGluR ligands on [3H]Glutamate binding. In contrast, Figure 2(c) shows that isoborneol (0.0008 mg/mL) only interacted with NMDA. At higher concentrations (1 mg/mL) isoborneol interacted with AMPA and KA.

As shown in Figure 3(a), valerian extract (0.05 mg/mL) increased [3H]Glutamate binding by 81%, while at 10 mg/mL, it decreased the binding by 28%. Valerian extract (0.05 mg/mL) in presence of LCCG-I, a Group II metabotropic glutamate receptor agonist, decreased (19%) [3H]Glutamate binding. This effect was not observed with
QA or L-AP4. In contrast, at 10 mg/mL, the valerian extract, in presence of QA, increased the glutamate binding (28%), while in presence of LCCG-I, it decreased [3H]Glutamate binding by 16%. A detailed evaluation of Group II mGluR-Valerian interaction (Figure 3(a) - Insert) confirmed a marked decrease in the [3H]Glutamate binding when valerian extracts (0.001 mg/mL) were in presence of DCG-IV (28%) and EGLU (38%), a highly selective Group II metabotropic glutamate receptor agonist and antagonist, respectively.

In presence of QA, valeronic acid (0.008 mg/mL) significantly increased the [3H]Glutamate binding by 54% as shown in Figure 3(b). Similarly, isoborneol at 0.0008 and 1 mg/mL increased [3H]Glutamate binding by 49% and 64%, respectively (Figure 3(c)). Interestingly, isoborneol indiscriminately interacted with all the mGluR ligands, and at 0.0008 mg/mL, isoborneol interacted with QA and markedly decreased (14%) [3H]Glutamate binding. In addition, isoborneol interacted with all the mGluR agonists (LCCG-I, DCG-IV and spaglumic) and antagonist (EGLU). Isoborneol also strongly interacted with L-AP4 at both concentrations (0.0008 mg/mL and 1 mg/mL) and resulted in an increased [3H]Glutamate binding (37% and 46%, resp.).

4. Discussion

Among 150 potentially active phytochemicals, constituents identified in the Valerian's roots are (1) iridoid valepotriates (0.5%–2.0%): valtrate, isovaltrate, didrovaltrate, acevaltrate and others and (2) volatile essential oil (0.2%–2.8%) divided in (a) monoterpines: borneol and bornyl acetate and (b) sesquiterpenes: valerenic, valeric, isovaleric and acetoxyvaleric acids: valerenal, valeranone, and kessyl glycol [14, 15]. Some sesquiterpenes, such valerenic acid, influence serotonin and noradrenaline levels, reduce locomotion, and anxiety, and increase pentobarbital sleeping time of mice [16, 17]. Similarly, other constituents, such as valepotriates potentiate hexobarbital anesthesia, suppress aggression, have anticonvulsant effects against pentylentetrazole- and strychnine-induced seizures, increase thiorpental sleeping time, reduce motility, and have dose-dependent sedative effects [17–19]. In addition, valepotriates and their decomposition products, baldrinals and homobaldrinals, reduced the total HAM-A (Hamilton anxiety scale) in a small clinical trial [20] and increased the time spent in open arms when elevated plus maze test was performed in rats [19]. Therefore, it is most likely that valerian's pharmacological properties are due to the additive effects of multiple active constituents and not one alone [21].

Most of the Valerian effects described above are consistent with the enhancement of GABAA-mediated transmission [7, 22–24]. Cavadas and colleagues showed that valerian extracts bind to GABAA receptors [4], while other researchers found that valerian is a partial agonist of the 5-HT(3a) receptor [8] and promotes cell proliferation in the hippocampus of “depressive” rats [25]. Moreover, recent studies suggest that different components within the valerian extract mediate the activation of adenosine receptors [26, 27]. Indeed, many studies have been done to determine the interaction of valerian with different receptors, but none of them examined valerian-glutamate receptor interaction.

Our [3H]Glutamate displacement curve in presence of Valeriana officinalis demonstrated that valerian extracts increase glutamate binding from $8 \times 10^{-7}$ to $1 \times 10^{-1}$ mg/mL reaching a maximum $3\text{H} \text{Glutamate binding at } 1 \times 10^{-3}$ mg/mL (160%). Therefore, at these physiological attainable concentrations ($8 \times 10^{-7} \text{ to } 1 \times 10^{-1}$ mg/mL) valerian potentiates $3\text{H} \text{Glutamate binding. In contrast, different findings were obtained for valerenic acid and isoborneol. The } 3\text{H} \text{Glutamate displacement curves and the receptor selectivity obtained for valerian and its constituents, for instance, are very different from each other, suggesting that these constituents are not the compounds responsible for the increase in } 3\text{H} \text{Glutamate binding observed with valerian.}

The glutamatergic system plays an important role in anxiety pathogenesis [28]. It is suggested that the physiological and behavioral responses associated with anxiety are regulated by a balance between the inhibition produced by GABA and the excitation caused by glutamate. Treatments used to decrease excitability in neurons from the amygdala are achieved by increasing GABA neurotransmission. Alternatively, treatments to decrease the excitability can be obtained by decreasing the excitatory glutamatergic transmission. Therefore, decreasing excitatory neurotransmission in the CNS, by modulating the response produced by the glutamatergic receptors, is an alternative approach to produce anxiolysis and sedation. The glutamate receptors found in the amygdala produce excitatory and inhibitory actions, and the degree of ionotropic and metabotropic activation is an important factor to determine the amygdala cell excitability. Thus, the modulation of glutamate actions mediated by iGluR and mGluR represent a feasible alternative to treat anxiety states [12, 29].

Compounds that decrease glutamatergic transmission via blockade of NMDA have been reported to produce anxiolytic and antidepressant-like actions in animal tests and models [30, 31]. Our group demonstrated that valerian extract had modest inhibitory effects on $[3\text{H}] \text{MK-801 binding, an indicator of NMDA-valerian interaction [32]}. In 2004, Malva and colleagues reported that by decreasing neuronal network excitability through AMPA permeable Ca$^{2+}$ receptors, valerian preparations could contribute to neuroprotection and may be of therapeutic use in preventing glutamate-mediated degeneration related to aging or neurodegenerative disorders [33]. Now, our study confirms that in the presence of iGluR agonists, valerian extracts interact with KA and NMDA (0.05 mg/mL and 10 mg/mL, resp.). While isoborneol exhibited significant interactions with all iGluR, valerenic acid did not interact with iGluR agonists. Many studies suggest that metabotropic glutamate receptors are involved in anxiety [12, 34–36]. For this reason, we performed receptor-binding assays with valerian extracts in presence of different types of metabotropic glutamate receptors. In this study, we demonstrated that valerian extracts, in presence of mGluR ligands, exhibited significant interaction with QA (Group I mGluR) and LCCG-I (Group II mGluR). Valerenic acid selectively interacts with QA. However, isoborneol interacts with all mGluR receptors. Our
results clearly demonstrated that *Valeriana officinalis* and it constituents (valeric acid and isoborneol) interact with Group I and II mGluR, which supports previous studies showing the role of Group I and II mGluR in anxiety [35, 37].

The pharmacological effects of *Valeriana officinalis* extracts in $[^{3}H]$Glutamate binding are not conventional and binding selectivity (agonist/antagonist) or synergism occurring in the complex mixture of phytochemical constituents. The biphasic $[^{3}H]$Glutamate displacement curve obtained in presence of valerian represents an example of the interactions that occur in an extract which could not be evident when single constituents are studied in isolation. This study exclusively used receptor-binding assays to determine ligand-receptor interactions, but functionalities studies are being conducted to characterize them.

Our results confirm the hypothesis of valerian interaction with the glutamatergic receptors, suggesting a possible mechanism by which valerian extracts produce their effects. Val-mGluR interactions may represent a novel alternative for the treatment of anxiety. Further studies with fractions of valerian extract should be done to evaluate the interactions between a group of compounds and their effects on receptor-binding selectivity.

### Abbreviations

**AMPA:** (α-amino-3-hydroxyl-5-methylisoxazole-4-propionic acid)

**CAM:** Complementary alternative medicine

**CNS:** Central nervous system

**DCG-IV:** (2S,2′R,3′R)-2-(2′,3′-Diacboxycyclopropyl)glycine

**EGLU:** (2S)-a-Ethylglutamic acid

**Group II mGluR:** Metabotropic glutamate receptors (2/3)

**Group I mGluR:** Metabotropic glutamate receptor (1/5)

**iGluR:** Ionotropic glutamate receptor

**KA:** Kainic acid

**L-AP4:** L- (+)-2-Amino-4-phosphonobutyric acid

**LCCG-I:** (2S,1′S,2′S)-2-(Carboxycyclopropyl)glycine

**mGluR:** Metabotropic glutamate receptor

**NCCAM:** National Center of Complementary Alternative Medicine

**NMDA:** N-methyl-D-aspartic acid

**QA:**quisqualic acid: (2S)-2-amino-3-(3,5-dioxo-1,2,4-oxiazolidin-2-yl)propanoic acid

**Spaglumic acid:** (N-Acetyl-L-aspartyl-L-glutamic acid).

### Acknowledgments

This work was supported in part by the Research Centers for Minority Institution (RCMI/NIH Grant no. G12 RR03051), Institutional Minority Biomedical Research Support (MBRS-RISE) Program at the University of Puerto Rico, Medical Sciences Campus (Grant no. 2 R25 GM061838-05) and Humacao Campus (Grant no. 1 R25 GM 075348-01A1). The authors would like to thank Veronika Butterweck, Ph.D., and Philip C. Specht, Ph.D., for their help with the revision of this paper.

### References

[1] P. J. Houghton, “The scientific basis for the reputed activity of valerian,” *Journal of Pharmacy and Pharmacology*, vol. 51, no. 5, pp. 505–512, 1999.

[2] P. J. Houghton, “The biological activity of valerian and related plants,” *Journal of Ethnopharmacology*, vol. 22, no. 2, pp. 121–142, 1988.

[3] P. D. Leathwood and F. Chauffard, “Aqueous extract of valerian reduces latency to fall asleep in man,” *Planta Medica*, no. 2, pp. 144–148, 1985.

[4] C. Cavadas, I. Araujo, M. D. Cotrim et al., “In vitro study on the interaction of *Valeriana officinalis* L. extracts and their amino acids on GABA(A) receptor in rat brain,” *Arzneimittel-Forschung*, vol. 45, no. 7, pp. 753–755, 1995.

[5] S. Bent, A. Padula, D. Moore, M. Patterson, and W. Mehling, “Valerian for sleep: a systematic review and meta-analysis,” *American Journal of Medicine*, vol. 119, no. 12, pp. 1005–1012, 2006.

[6] L. S. Miyasaka, A. N. Atallah, and B. G. Soares, “Valerian for anxiety disorders,” *Cochrane Database of Systematic Reviews*, no. 4, Article ID CD004515, 2006.

[7] S. Khom, I. Baburin, E. Timin et al., “Valerenic acid potentiates and inhibits GABA receptors: molecular mechanism and subunit specificity,” *Neuropharmacology*, vol. 53, no. 1, pp. 178–187, 2007.

[8] B. M. Dietz, G. B. Mahady, G. F. Pauli, and N. R. Farnsworth, “Valerian extract and valerenic acid are partial agonists of the 5-HT6 receptor in vitro,” *Molecular Brain Research*, vol. 138, no. 2, pp. 191–197, 2005.

[9] M. Hattesohi, B. Feistel, H. Sievers, R. Lehnfeld, M. Hegger, and H. Winterhoff, “Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties,” *Phytotherapy*, vol. 15, no. 1-2, pp. 2–15, 2008.

[10] K. Murphy, Z. J. Kubin, J. N. Shepherd, and R. H. Ettinger, “Valeriana officinalis root extracts have potent anxiolytic effects in laboratory rats,” *Phytotherapy*, vol. 17, no. 8-9, pp. 674–678, 2010.

[11] A. Diaper and I. Hindmarch, “A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults,” *Phytotherapy Research*, vol. 18, no. 10, pp. 831–836, 2004.

[12] C. J. Swanson, M. Bures, M. P. Johnson, A. M. Linden, J. A. Monn, and D. D. Schoep, “Metabotropic glutamate receptors as novel targets for anxiety and stress disorders,” *Nature Reviews Drug Discovery*, vol. 4, no. 2, pp. 131–144, 2005.

[13] M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” *Analytical Biochemistry*, vol. 72, no. 1-2, pp. 248–254, 1976.

[14] J. Bruneton, Ed., *Pharmacognosy: Phytochemistry, Medicinal Plants*, Lavoisier, London, UK, 2nd edition, 1999.
Evidence-Based Complementary and Alternative Medicine

[15] M. Marder, H. Viola, C. Wasowski, S. Fernández, J. H. Medina, and A. C. Paladini, "6-Methylapigenin and hesperidin: New valeriana flavonoids with activity on the CNS," Pharmacology Biochemistry and Behavior, vol. 75, no. 3, pp. 537–545, 2003.

[16] D. Benke, A. Barberis, S. Kopp et al., “GABA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts,” Neuropharmacology, vol. 56, no. 1, pp. 174–181, 2009.

[17] H. Hendriks, R. Bos, and D. P. Allersma, “Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis,” Planta Medica, vol. 42, no. 1, pp. 62–68, 1981.

[18] J. Leuschner, J. Muller, and M. Rudmann, “Characterisation of the central nervous depressant activity of a commercially available valerian root extract,” Arzneimittel-Forschung, vol. 43, no. 6, pp. 638–641, 1993.

[19] R. Andreatini and J. R. Leite, “Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal,” European Journal of Pharmacology, vol. 260, no. 2–3, pp. 233–235, 1994.

[20] R. Andreatini, V. A. Sartori, M. L. V. Seabra, and J. R. Leite, “Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study,” Phytotherapy Research, vol. 16, no. 7, pp. 650–654, 2002.

[21] M. Spinella, “The importance of pharmacological synergy in psychoactive herbal medicines,” Alternative Medicine Review, vol. 7, no. 2, pp. 130–137, 2002.

[22] M. S. Santos, F. Ferreira, A. P. Cunha, A. P. Carvalho, and T. Macedo, “An aqueous extract of valerian influences the transport of GABA in synaptosomes,” Planta Medica, vol. 60, no. 3, pp. 278–279, 1994.

[23] M. S. Santos, F. Ferreira, A. P. Cunha, A. P. Carvalho, C. F. Ribeiro, and T. Macedo, “Synaptosomal GABA release as influenced by valerian root extract—involved of the GABA carrier,” Archives Internationales de Pharmacodynamie et de Therapie, vol. 327, no. 2, pp. 220–231, 1994.

[24] J. G. Ortiz, J. Nieves-Natal, and P. Chavez, “Effects of Valeriana Officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release,” Neurochemical Research, vol. 24, no. 11, pp. 1373–1378, 1999.

[25] J. Y. Tang, Y. S. Zeng, Q. G. Chen, Y. A. Qin, S. J. Chen, and Z. Q. Zhong, “Effects of Valerian on the level of 5-hydroxytryptamine, cell proliferation and neurons in cerebral hippocampus of rats with depression induced by chronic mild stress,” Journal of Chinese Integrative Medicine, vol. 6, no. 3, pp. 283–288, 2008.

[26] K. Sichardt, Z. Vissiennou, U. Koetter, A. Brattström, and K. Nieber, “Modulation of postsynaptic potentials in rat cortical neurons by valerian extracts macerated with different alcohols: involvement of adenosine A1- and GABAA-receptors,” Phytotherapy Research, vol. 21, no. 10, pp. 932–937, 2007.

[27] S. K. Lacher, R. Mayer, K. Sichardt, K. Nieber, and C. E. Müller, “Interaction of valerian extracts of different polarity with adenosine receptors: identification of isoavlar as an inverse agonist at A1 receptors,” Biochemical Pharmacology, vol. 73, no. 2, pp. 248–258, 2007.

[28] V. Bergink, H. J. G. M. Van Megen, and H. G. M. Westenberg, "Glutamate and anxiety," European Neuropsychopharmacology, vol. 14, no. 3, pp. 175–183, 2004.

[29] R. E. Nordquist, T. Steckler, J. G. Wettstein, C. Mackie, and W. Spooren, "Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety," Psychopharmacology, vol. 199, no. 3, pp. 389–402, 2008.

[30] F. S. Guimaraes, A. P. Carobrez, J. C. De Aguiar, and E. G. Graeff, "Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey," Psychopharmacology, vol. 103, no. 1, pp. 91–94, 1991.

[31] J. L. Wiley, “Behavioral pharmacology of N-Methyl-D-aspartate antagonists: implications for the study and pharmacotherapy of anxiety and schizophrenia,” Experimental and Clinical Psychopharmacology, vol. 5, no. 4, pp. 365–374, 1997.

[32] J. G. Ortiz, N. Rassi, P. M. Maldonado, S. González-Cabera, and I. Ramos, “Commercial Valerian interactions with [3H]flunitrazepam and [3H][MK-801 binding to rat synaptic membranes," Phytotherapy Research, vol. 20, no. 9, pp. 794–798, 2006.

[33] J. O. Malva, S. Santos, and T. Macedo, “Neuroprotective properties of Valeriana officinalis extracts,” Neurotoxicity Research, vol. 6, no. 2, pp. 131–140, 2004.

[34] M. J. Fell, K. A. Svensson, B. G. Johnson, and D. D. Schoepp, “Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist ((1R,4S,5S,6S)-4-amino-2-sulfonyl-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039),” Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 1, pp. 209–217, 2008.

[35] A. Palucha and A. Pilc, “Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs,” Pharmacology and Therapeutics, vol. 115, no. 1, pp. 116–147, 2007.

[36] W. P. J. M. Spooren, A. Vassout, H. C. Neijt et al., “Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 3, pp. 1267–1275, 2000.

[37] E. Chojnacka-Wójcik, A. Kłodzinska, and A. Pilc, “Glutamate receptor ligands as anxiolytics,” Current Opinion in Investigational Drugs, vol. 2, no. 8, pp. 1112–1119, 2001.